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Abstract
The incidence of candidiasis has dramatically increased and bloodstream infections due to different species of
Candida are becoming a prime cause of morbidity and mortality in different types of immunocompromised patients.
Azole and echinocandin drug resistance accounts for the dramatic increase in incidence of nosocomial bloodstream
candidiasis found in recent years. Cell wall constitutes the barrier between the yeast and the host and resistant
strains change the proteome of this compartment. In the last decade different proteomic platforms have been
applied to study cell wall and markers of resistance to drugs have been pointed out. Modulation of these proteins
seem to suggest that although resistance is based on a specific mutation able to counteract the toxicity of the
antifungal drug, a set of other molecular modifications takes place contemporary or subsequently the establishment
of the resistance and seems to support the viability of the resistant yeast. Profiled proteins by proteomics may be
valuable in design therapy using classical antifungal along with complementary drugs able to abolish pathways that
strengthen the resistance and attenuate virulence of the mutated cell.
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Introduction
Candida albicans, a dimorphic opportunistic human pathogen
yeast, is the most prominent cause of oro-pharyngeal, vaginal and
invasive candidiasis in man [1]. In particular, oro-pharyngeal
infections are very common in human immunodeficiency virus (HIV)-
infected individuals and patients with acquired immune deficiency
syndrome (AIDS), while deep-seated infections are frequent in
neutropenic patients under chemotherapy [2,3].
Currently available therapies reside on antifungal drugs belonging
to azole and echinocandin families that interfere with different aspects
of fungal metabolism.
In Candida, azole antifungals target protein Erg11p involved in the
biosynthesis of ergosterol, the main sterol of the membranes of the
fungal cell. This protein is located at the inner face of the membrane of
the smooth endoplasmic reticulum, engaged in the synthesis of lipids,
including oils, phospholipids and steroids. Erg11p, a member of the
cytochrome P450 family, is a hemoprotein that has an iron atom as
prosthetic group, whose function is to fix the dioxygen necessary for
the enzymatic activity [4]. Echinocandin drugs are lipopeptides that
inhibit glucan synthase, which is responsible for the biosynthesis of
ß-1,3-D-glucan, a major structural component of fungal cell wall [5].
The echinocandin target, ß-1,3-D-glucan synthase, is a fungal-specific
multi-subunit enzyme complex comprised of Rho, a GTP-binding
protein, which helps regulate the overall activity of glucan synthase
and a catalytic subunit Fks encoded by three related genes, FKS1,
FKS2, and FKS3 [6].
Candida resistance to antifungal drugs
The raise of resistant strains to these drugs account for the dramatic
increase in incidence of nosocomial bloodstream candidiasis found in
recent years [7]. Acquired resistance in Candida has been described
and underlying mechanisms have been characterized for both azoles
and echinocandins. For the azoles, three different mechanisms have
been described: 1) mutations of ERG11 that reduce the binding affinity
of the protein to azole antifungals. These mutations are not randomly
distributed over the ERG11 gene but are preferentially clustered within
three regions [4] ; 2) overexpression of ERG11, leading to an increase
of the intracellular concentration of the target protein. Two
independent mechanisms drive ERG11 overexpression: the former is
ERG11 gene duplication while the latter depends on the regulation of
the ergosterol biosynthesis pathway; 3) overexpression of efflux
membrane transporters for azole drug that carrying azole outside the
cell decreases their intracellular concentration. Two families of drug
efflux transporters can be distinguished in yeasts [4]: the ATP Binding
cassette (ABC) transporters, encoded by the genes CDR1 and CDR2 in
Candida albicans and the major facilitator superfamily (MFS)
transporter encoded by MDR1 gene [8].
In the individual isolate these mechanisms often act in concert
leading to stepwise increases in minimal inhibition concentration
(MIC) and broadening of the azole resistance spectrum.
For the echinocandins only target gene mutations of ß-1,3-D-glucan
synthase are responsable for resistance in isolates and produce
modification of the catalytic Fsk subunit (Fks1 and Fks2) of glucan
synthase [9]. Unlike azole antifungal agents, echinocandins are not
substrates for multidrug transporters [10]. Echinocandin resistance is
conferred by characteristic amino acid substitutions in Fks subunits
[11], which induce elevated MIC values (10–100 fold) and reduce the
sensitivity of glucan synthase (IC50) to drug by 50- to 3,000-fold [12].
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Characteristic mutations in FKS genes are prominently associated with
reduced clinical response [13].
Molecular studies of Candida cell wall
To better understand at molecular level the organization of the
fungal cell once drug resistance has been established, cell wall
represents a first choice as this compartment constitutes her barrier
between the yeast the and host [14]. This essential organelle maintains
cell shape strengthening its structure, limits permeability thereby
retaining periplasmic proteins and protects from host degrading
enzymes. The cell wall is mainly composed of beta-1,3- and beta-1,6-
glucans and by small amount of chitin long with proteins that can be
grouped in three main classes: i) glycophosphatidylinositol (GPI)-
anchored proteins(GPI-CWPs), the majority of them mannosylated,
and covalently linked to the beta-1,6-glucan through the GPI anchor;
ii)proteins with Internal Repeats (PIR) directly linked to the beta-1,3-
glucan iii) CWPs lacking a covalent attachment to the polysaccharide
matrix [11,15].
Studies for identification of CWPs that change their expression in
resistance strains may be useful to determine biological markers
associate to drug resistance with a diagnostic value and to find out
antigenic epitopes that can be used to evoke antibodies able to contain
Candida invasion. Furthermore, determination of the functional
properties of differently expressed CWP may highlight metabolic
pathways involved in sustaining the virulence of the yeast. A suitable
strategy to study modulation of cell wall proteins in experimental
resistance strains and clinical isolates is represented by the proteomic
approach that can yield a complete comparative picture of the
differential expressed proteins between sensitive and resistant strains.
Different proteomic platforms have been applied to study different
topics of Candida albicans as reported in 137 published in PubMed in
the last decade (crossing terms: proteomics and Candida albicans). 32
out of these 137 papers, are indeed focused on cell wall structure
[16,17], metabolism [18], surface immunogenic proteins and proteins
enriched in the cell wall [19] and conveyed outside in extracellular
vesicles [20]. The limited number of articles, despite the significance
and importance of this compartment in Candida metabolism, may
reside on the difficulty of preparation and purification of the cell wall
proteome since most of the proteins, GPI-CWP and PIR are covalently
linked to the glucan moiety. In particular scant information are still
available on changes of cell wall proteoma in antifungal resistant
strains.
Thanks to a 2D-electrophoretic based proteomic platform, two
proteins, bgl2p [21] and rhd3/pga29 [22], whose expression clearly
increase on the cell wall in micafungin resistant strains have been
recently identified and up to now they represent the main cell wall
markers in the resistance to this antifungal drug. Bgl2p is an endo-1,3-
glucanase and glucanosyltransferase that introduces 1,6-linkages in
1,3-glucan chains and participates in cross-linking of the glucan
component of the cell wall. Bgl2p has also been found in exosomes
released from Candida albicans [20]. Deletion of BGL2 does not
obviously affect cell morphology, whereas its over-expression is
harmful for cell viability. It is noteworthy that an increase of bgl2p has
been observed also in fluconazole resistant strains indicating a
beneficial role of this protein probably to favour the re-arrangment of
cell wall in both resistant strains. Antibodies against this protein
represent an accurate diagnostic biomarkers in patients with systemic
candidiasis along with anti-wall phosphoglicerate kinase antibodies
and high seropositivity to anti-bgl2p modulate anti-wall enolase
response lowering risk of fatality in these patients [22].
Rhd3/pga29, the latter biomarker of micafungin resistance, has been
recently identified by us [23]. For this protein, a functional role has not
yet been assigned. However, deletion of gene attenuated the
pathogenicity and diminished the production of pro-inﬂammatory
cytokines by the host indicating a peculiar role of this protein in the
virulence of the fungus [24]. An up-regulation of this protein occurs in
presence of iron while it is down-regulated during the yeast to hyphae
transition. Rhd3/pga29 increase is peculiar of the resistance to
micafungin since in fluconazole resistant strains there is not any
increase of this marker on the cell wall. This different response
indicates aspecific molecular adaptation regarding Rhd3/pga29 levels
on the cell wall of resistant cells to the two antifungal drugs.
Modulation of these proteins seem to suggest that although
resistance is based on a specific mutation able to counteract the toxicity
of the antifungal drug, a set of other molecular modifications takes
place contemporary or subsequently the establishment of the resistance
and seems to support the viability of the resistant yeast cell. More
sensitive and quantitative proteomic approaches will be helpful in
widening the list of proteins involved in the re-organization of the cell
in echinocandins and azoles resistance. Identification of these proteins
may help in defining the molecular processes involved in resistant
strains fitness. These new technologies could be applied also to identify
down-regulated protein that, if antigenic, could allow the fungus to
escape immunogenic response.
Conclusion
Profiled proteins modulated in resistant strains may be valuable in
design therapy using classical antifungal along with complementary
drugs able to abolish pathways that strengthen the resistance and
attenuate virulence of the mutated cell. This strategy may succeed in
overcoming Candida albicans invasion mainly in
immunocompromised patients where resistant strains to both azoles
and echinocandins frequently occur.
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